SCHEMBL2856446

SCHEMBL2856446

CC(=O)Nc1nc2ccc(Oc3cc(N)c(F)cc3F)nc2s1

nearest known ligand 0.46

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
DYRK1A Q13627 11/20 0.46
PDPK1 O15530 1/20 0.46
BRAF P15056 1/20 0.44
CLK1 P49759 1/20 0.43
CYP3A4 P08684 3/20 0.41
NPC1 O15118 2/20 0.41
CYP1A2 P05177 2/20 0.41
CYP2C19 P33261 2/20 0.41
RAB9A P51151 2/20 0.41
HTT P42858 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
PIK3CG P48736 5/20 0.41
PIK3CA P42336 4/20 0.41
PIK3CB P42338 1/20 0.41
PI4KB Q9UBF8 1/20 0.41
CYP2C9 P11712 1/20 0.40
FSCN1 Q16658 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2859799 0.91 ROCK2 (0.44) DYRK1APDPK1BRAFCLK1CYP3A4
SCHEMBL2858259 0.87 CLK1 (0.51) DYRK1APDPK1BRAFCLK1CYP3A4
SCHEMBL2862242 0.85 BRAF (0.47) DYRK1APDPK1BRAFCYP3A4NPC1
SCHEMBL2855636 0.85 BRAF (0.54) DYRK1APDPK1BRAFCLK1CYP3A4
SCHEMBL2856064 0.84 BRAF (0.44) DYRK1APDPK1BRAFCLK1CYP3A4
SCHEMBL2851274 0.81 BRAF (0.45) DYRK1APDPK1BRAFCYP3A4NPC1
SCHEMBL3510603 0.81 BRAF (0.43) DYRK1APDPK1BRAFCYP3A4NPC1
SCHEMBL2854440 0.80 ROCK2 (0.48) BRAFNPC1RAB9ASMN1; SMN2
SCHEMBL2851233 0.78 BRAF (0.54) BRAFNPC1RAB9ASMN1; SMN2
SCHEMBL3512217 0.77 BRAF (0.46) DYRK1APDPK1BRAFCYP3A4NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2184285-B1 HETEROCYCLIC COMPOUND AND USE THEREOF TAKEDA PHARMACEUTICAL (JP) 2015-11-04 EP disclosed
US-8344135-B2 Heterocyclic compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-01-01 US disclosed
US-20100249119-A1 HETEROCYCLIC COMPOUND AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-09-30 US disclosed
EP-2184285-A1 HETEROCYCLIC COMPOUND AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2010-05-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100249119-A1 HETEROCYCLIC COMPOUND AND USE THEREOF BRAF, NRAS, RAF1 DYRK1A 2109/4885PDPK1 449/4885BRAF 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.